Serum complement C4b, fibronectin, and prolidase are associated with the pathological changes of pulmonary tuberculosis

BMC Infectious Diseases

Ji-Cheng Li²  Ze-Peng Ping²  Ji-Yan Liu²  Xing Zhang²  Zhong-Liang Chen²  Zhong-Jie Li²  Ting-Ting Jiang²  Dan-Dan Xu²  Xiu-Yun Yang³  Li-Liang Wei⁵  Xiang Li⁴  Yan-Yuan Li¹  Chong Wang² 

[1] Department of Pathology, First Affiliated Hospital, Zhejiang University, Hangzhou 310003, P.R. China;Institute of Cell Biology, Zhejiang University, Hangzhou 310058, P.R. China;Department of Respiratory Medicine, Tongde Hospital of Zhejiang Province, Hangzhou 310012, P.R. China;Key Laboratory of Gastroenteropathy, Zhejiang Province People’s Hospital, Hangzhou 310012, P.R. China;The Sixth Hospital of Shaoxing, Shaoxing 312000, P.R. China

关键词: Cavity;    Granuloma;    Prolidase;    Fibronectin;    Complement C4b;    Pulmonary tuberculosis;    Serum;   

Others  :  1134815
DOI  :  10.1186/1471-2334-14-52

 received in 2013-06-24, accepted in 2014-01-30,  发布年份 2014

【 摘 要 】

Background

Mycobacterium tuberculosis infection can activate the immune system, leading to characteristic pathological changes such as inflammatory granuloma, caseous necrosis, and cavity formation.

Methods

Clinical data of 187 cases of pulmonary tuberculosis (PTB) were analyzed using statistical methods, while serum levels of complement C4b (C4b), fibronectin (FN), and prolidase (PEPD) were detected using the ELISA method among the control, minimal PTB, moderate PTB, and advanced PTB groups.

Results

We found significantly higher levels of serum C4b and PEPD (P = 0.018, P = 0.003), and significantly lower levels of serum FN (P < 0.001) in PTB patients. Furthermore, the serum levels of 3 proteins were significantly different among 3 PTB groups. FN level was significantly higher in the moderate PTB group, compared with patients in the minimal and advanced PTB groups (P < 0.05, P < 0.01). PEPD level was significantly higher in the moderate PTB group, compared with the minimal PTB group (P < 0.05). Analysis of clinical data showed that serum albumin, C-reactive protein (CRP), prealbumin, and C4 were significantly higher (P < 0.05), while serum globulin was significantly lower in patients with PTB (P < 0.001). A significant negative correlation was found between C4b and albumin, prealbumin. On the other hand, a significant positive correlation was found between C4b and globulin, CRP, PEPD, as well as between PEPD and CRP (P < 0.05).

Conclusions

Our study showed that C4b, FN, and PEPD are associated with tissue damage, granuloma formation, and cavity formation, respectively, in patients with PTB. The present study provides a new experimental basis to understand the pathogenesis and pathological changes of PTB.

【 授权许可】

   
2014 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]World Health Organization: Global tuberculosis report 2012. http://www.who.int/tb/publications/global_report/gtbr12_main.pdf webcite
• [2]Technical Guidance Group of the Fifth National TB Epidemiological Survey, The Office of the Fifth National TB Epidemiological Survey: The fifth national tuberculosis epidemiological survey in 2010. Chin J Antituber 2012, 34(8):485-508.
• [3]Dunkelberger JR, Song WC: Complement and its role in innate and adaptive immune responses. Cell Res 2010, 20(1):34-50.
• [4]Kleinnijenhuis J, Oosting M, Joosten LA, Netea MG, Van Crevel R: Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol 2011, 2011:405310.
• [5]Vankayalapati R, Barnes PF: Innate and adaptive immune responses to human Mycobacterium tuberculosis infection. Tuberculosis (Edinb) 2009, 89(Suppl 1):S77-S80.
• [6]Hernandez-Pando R, Orozco H, Aguilar D: Factors that deregulate the protective immune response in tuberculosis. Arch Immunol Ther Exp (Warsz) 2009, 57(5):355-367.
• [7]Means TK, Wang S, Lien E, Yoshimura A, Golenbock DT, Fenton MJ: Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol 1999, 163(7):3920-3927.
• [8]Constantoulakis P, Filiou E, Rovina N, Chras G, Hamhougia A, Karabela S, Sotiriou A, Roussos C, Poulakis N: In vivo expression of innate immunity markers in patients with Mycobacterium tuberculosis infection. BMC Infect Dis 2012, 10:243.
• [9]Lachmann PJ: Microbial immunology: a new mechanism for immune subversion. Curr Biol 1998, 8(3):99-101.
• [10]Taylor JL, Hattle JM, Dreitz SA, Troudt JM, Izzo LS, Basaraba RJ, Orme IM, Matrisian LM, Izzo AA: Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect Immun 2006, 74(11):6135-6144.
• [11]De Groote MA, Nahid P, Jarlsberg L, Johnson JL, Weiner M, Muzanyi G, Janjic N, Sterling DG, Ochsner UA: Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS One 2013, 8(4):e61002.
• [12]O’Regan AW, Chupp GL, Lowry JA, Goetschkes M, Mulligan N, Berman JS: Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J Immunol 1999, 162(2):1024-1031.
• [13]Grosset J: Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob Agents Chemother 2003, 47(3):833-836.
• [14]Kumar V, Abbas AK, Fausto N, Aster JC: Acute and chronic inflammation. In Robbins and Cotran Pathologic basis of disease. 7th edition. Philadelphia, PA: Elsevier Saunders; 2005:82.
• [15]Ministry of Health of the People’s Republic of China: Diagnostic criteria for pulmonary tuberculosis. http://www.moh.gov.cn/publicfiles///business/cmsresources/zwgkzt/cmsrsdocument/doc3242.pdf webcite
• [16]Falk A, O’Connor JB, Pratt PC: Classification of pulmonary tuberculosis. In Diagnostic standards and classification of tuberculosis. 12, vol. 6th edition. New York: National Tuberculosis and Respiratory Disease Association; 1969:68-76.
• [17]Hussain R, Hasan R, Khurshid M, Sturm AW, Ellner JJ, Dawood G: Pulmonary tuberculosis in a BCG vaccinated area: relationship of disease severity with immunological and hematological parameters and drug resistance patterns. Southeast Asian J Trop Med Public Health 1996, 27(2):257-262.
• [18]Kingery SE, Wu YL, Zhou B, Hoffman RP, Yu CY: Gene CNVs and protein levels of complement C4A and C4B as novel biomarkers for partial disease remissions in new-onset type 1 diabetes patients. Pediatr Diabetes 2012, 13(5):408-418.
• [19]Yoon SH, Lee NK, Yim JJ: Impact of sputum gross appearance and volume on smear positivity of pulmonary tuberculosis: a prospective cohort study. BMC Infect Dis 2012, 12:172. BioMed Central Full Text
• [20]Lucena S, Arocha Pinango CL, Guerrero B: Fibronectin. Structure and functions associated to hemostasis. Review. Invest Clin 2007, 48(2):249-262.
• [21]Kim HY, Wolf G: Vitamin A deficiency alters genomic expression for fibronectin in liver and hepatocytes. J Biol Chem 1987, 262(1):365-371.
• [22]Tanaka T, Sakurada S, Kano K, Takahashi E, Yasuda K, Hirano H, Kaburagi Y, Kobayashi N, Hang NT, Lien LT, et al.: Identification of tuberculosis-associated proteins in whole blood supernatant. BMC Infect Dis 2011, 11:71. BioMed Central Full Text
• [23]Al Adnani MS: Concomitant immunohistochemical localization of fibronectin and collagen in schistosome granulomata. J Pathol 1985, 147(2):77-85.
• [24]Rojas RE, Thomas JJ, Gehring AJ, Hill PJ, Belisle JT, Harding CV, Boom WH: Phosphatidylinositol mannoside from Mycobacterium tuberculosis binds alpha5beta1 integrin (VLA-5) on CD4+ T cells and induces adhesion to fibronectin. J Immunol 2006, 177(5):2959-2968.
• [25]Myara I, Myara A, Mangeot M, Fabre M, Charpentier C, Lemonnier A: Plasma prolidase activity: a possible index of collagen catabolism in chronic liver disease. Clin Chem 1984, 30(2):211-215.
• [26]Gumus S, Yaman H, Ozcan O, Deniz O, Karaman B, Cakir E, Tozkoparan E, Ozkan M, Bilgic H: Serum prolidase activity in patients with pulmonary tuberculosis. Scand J Clin Lab Invest 2011, 71(6):467-472.
• [27]Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV: Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004, 38(10 Suppl 3):S158-S168.